Study of Liposomal Irinotecan Combined with Apatinib in the Treatment of Extensive Stage Small Cell Lung Cancer After First-line Progression
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to observe the efficacy and safety of liposomal irinotecan combined with apatinib in the treatment of extensive stage small cell lung cancer progressed from first-line regimen.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Age range of 18-75 years;
• Expected survival period ≥ 12 weeks;
• At least one measurable lesion (according to RECIST V 1.1);
• For patients who have failed first-line or second-line treatment.
Locations
Other Locations
China
Second Affiliated Hospital of Zhejiang University
RECRUITING
Hangzhou
Contact Information
Primary
Xian Zhong
zhongxian_2000@163.com
86-571-86993769
Time Frame
Start Date: 2024-12-28
Estimated Completion Date: 2027-12
Participants
Target number of participants: 30
Treatments
Experimental: Liposomal Irinotecan and Apatinib
Related Therapeutic Areas
Sponsors
Leads: Second Affiliated Hospital, School of Medicine, Zhejiang University